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DObjective: The present analysis of the Surgical Treatment for Ischemic Heart Failure randomized trial data
examined the left ventricular volumes at baseline and 4 months after surgery to determine whether any magni-
tude of postoperative reduction in end-systolic volume affected survival after coronary artery bypass grafting
alone compared with bypass grafting plus surgical ventricular reconstruction.
Methods: Of the 1000 patients randomized, 555 underwent an operation and had a paired imaging assessment
with the same modality at baseline and 4 months postoperatively. Of the remaining 455 patients, 424 either died
before the 4-month study or did not have paired imaging tests and were excluded, and 21 were not considered
because they had died before surgery or did not receive surgery.
Results: Surgical ventricular reconstruction resulted in improved survival compared with coronary artery by-
pass grafting alone when the postoperative end-systolic volume index was 70 mL/m2 or less. However, the op-
posite was true for patients achieving a postoperative volume index greater than 70 mL/m2. A reduction in the
end-systolic volume index of 30% or more compared with baseline was an infrequent event in both treatment
groups and did not produce a statistically significant survival benefit with ventricular reconstruction.
Conclusions: In patients undergoing coronary artery bypass grafting plus surgical ventricular reconstruction,
a survival benefit was realized compared with bypass alone, with the achievement of a postoperative end-
systolic volume index of 70 mL/m2 or less. Extensive ventricular remodeling at baseline might limit the ability
of ventricular reconstruction to achieve a sufficient reduction in volume and clinical benefit. (J Thorac Cardio-
vasc Surg 2013;146:1139-45)Supplemental material is available online.
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Dpopulation, including the broad range of baseline left
ventricular (LV) volumes, adequacy of LV volume
reduction achieved with SVR, and extent and severity of
baseline anterior wall asynergy. Additional controversy
stems from uncertainty about whether a target level exists
for the LV end-systolic volume index (ESVI) that should
be achieved after SVR, and whether a target level exists
for the percentage of LVESVI reduction from baseline.
Whether the surgical reduction in the LVESVI achieved
in STICH was sufficient remains an unanswered question.
Considerationmust be given to the fact that the left ventricle
might be made too small or allowed to remain too largewith
SVR.5,6 Moreover, a baseline threshold LVESVI might
exist, above which the ventricle might be too large to
benefit from SVR.7
To further explore these questions and the implications of
the STICH results, we evaluated the distribution of LV vol-
umes at baseline and 4 months postoperatively and the indi-
vidual reductions in LV volume with surgery to determine
whether a threshold post-SVR LVESVI, or any magnitude
of postoperative reduction in LVESVI, affected survival
after CABG plus SVR compared with CABG alone.METHODS
Patient Population
From September 12, 2002 to January 24, 2006, 1000 patients with cor-
onary artery disease amenable to revascularization, an ejection fraction
(EF) of 35% or less, and anterior akinesia or dyskinesia amenable to
SVR were randomized to receive CABG alone (n ¼ 499) or CABG plus
SVR (n ¼ 501). Follow-up continued through December 31, 2008 and
was complete for 99% of the randomized patients. The median duration
of follow-up was 48 months.1,8
Of the 979 patients who underwent surgery, 86 (8.8%) died before their
4-month follow-up study (Figure E1). Also, 16 and 107 patients, respec-
tively, did not have either a baseline or 4-month postoperative imaging
study suitable for end-systolic volume determination by 1 of the 3 blinded
imaging core laboratories for echocardiography, radionuclide imaging, or
cardiac magnetic resonance studies.7 Of the remaining 770 patients, 175
had a suboptimal baseline or follow-up imaging study (less than ‘‘fair’’
to ‘‘excellent’’ quality) and 40 did not have paired imaging studies using
the same modality. The present report focused only on the 555 patients
who had undergone surgery and had a paired imaging assessment at base-
line and 4 months postoperatively.
Imaging Studies
All patients were required to have an echocardiogram at baseline and
a repeat study at the 4-month follow-up point. Cardiac magnetic resonance1140 The Journal of Thoracic and Cardiovascular Surand radionuclide imaging at baseline and 4 months were also recommen-
ded. Because many patients had undergone studies with more than 1 imag-
ing modality, the ‘‘best available’’ value of LV volume and EF was
determined for each patient according to the study quality, as previously de-
scribed.7 Using this approach, 195 patients with paired cardiac magnetic
resonance studies, 276 with paired echocardiography studies, and 84
with paired radionuclide imaging studies were available for the analyses.
Statistical Analysis
The baseline characteristics are summarized as the mean  standard
deviation for continuous variables and frequencies (percentages) for cate-
gorical variables. The characteristics of the patients with paired baseline
and 4-month studies were compared with those without paired studies us-
ing the 2-sample t test for continuous variables and Fisher’s exact test for
categorical variables. Changes in the LV function parameters from baseline
to 4 months were compared using the paired t test. Cumulative event rates
were calculated using Kaplan-Meier estimates.9 Time-to-event data were
analyzed using the log-rank statistic, and the Cox proportional hazards
model was used to estimate hazard ratios (HRs) and 95% confidence inter-
vals (CIs).10 The interaction of treatment and ESVI was also assessed using
the Cox model.
Three patient groups were created corresponding to previously de-
scribed clinically accepted thresholds of baseline LV volumes (group 1,
LVESVI< 60 mL/m2; group 2, LVESVI, 60-90 mL/m2; and group 3,
LVESVI > 90 mL/m2).5,11,12 The baseline clinical characteristics and
the magnitude of change in LV volumes from preoperatively to
postoperatively were compared among these groups. Additionally, the
change in ESVI was analyzed according to the specific thresholds to
assess whether a differential effect (either benefit or harm) was present
for CABG plus SVR versus CABG alone, depending on the magnitude
of the reduction in LVESVI.
Kaplan-Meier mortality rates in the 2 treatment arms across the range of
the 4-month LVESVI were constructed by choosing a specific cohort size
(n ¼ 150) and plotting the 4-year Kaplan-Meier estimate at the median
postoperative LVESVI for that cohort. We then moved this cohort across
the entire range of LVESVIs, 1 patient at a time, each time adding the
next larger LVESVI value and removing the smallest value (similar to
a moving average). Using this method, we obtained a ‘‘smoothed’’ plot
of mortality for the 2 treatment arms as a function of the 4-month LVESVI.9
RESULTS
The baseline characteristics of the 555 patients with both
pre- and postoperative LVESVI data were similar (except
for New York Heart Association class III/IV, hypertension,
and diabetes) to those of the 424 excluded patients who had
undergone surgery but either died before the 4-month study
or did not have paired imaging tests using the same modal-
ity (Table 1). An additional 21 patients were not included in
either cohort because they had either died before receiving
surgery or did not receive surgery within 1 year of random-
ization. The survival was not similar between the 555 pa-
tients and the 424 excluded patients, reinforcing that the
555 patients were not a random sample of the 1000 patients
(Figure E2). For the 555 patients with paired studies, no dif-
ference was seen in survival between CABG alone and
CABG plus SVR (Figure E3).
The characteristics were similar for the 555 patients with
paired pre- and postoperative studies undergoing CABG
plus SVR or CABG alone and for the 3 patient subgroups
(Table E1). The average number of distal bypass graftsgery c November 2013
TABLE 1. Baseline characteristics stratified by paired pre- and
postoperative imaging status
Variable
Patients with
paired imaging
tests (n ¼ 555)
Excluded
patients
(n ¼ 424)
Total
population
(n ¼ 979)*
ESVI (mL/m2) 84  34 85  36 86  38
EDVI (mL/m2) 115  38 115  40 117  41
LVEF (%) 29  9 28  8 28  9
Age (y) 61.3  9.6 61.9  9.9 61.6  9.7
Female gender (%) 13.2 15.8 14.3
Previously documented MI (%) 86.0 88.7 87.1
Hypertension (%) 53.7y 65.3 58.7
Diabetes (%) 31.2y 38.7 34.4
Angina class III or IV (%) 48.7 50.7 49.5
NYHA class III or IV (%) 42.9y 55.4 48.3
Triple vessel disease (%) 64.9 62.5 63.8
Graft number (%)
1-2 26.9 30.1 28.3
3-5 71.1 69.7 70.5
6 2 0.2 1.2
MR 3þor 4þ (%) 18.0 17.2 17.7
Data presented asmean standard deviation or percentages. EDVI, End-diastolic vol-
ume index; ESVI, end-systolic volume index; LVEF, left ventricular ejection fraction;
MI, myocardial infarction;MR, mitral regurgitation; NYHA, New York Heart Associ-
ation. *Twenty-one patients did not undergo surgery within 1 year of randomization
and were not included in this tabulation of baseline characteristics. yP<.05, Fisher’s
exact test (comparisons between paired cohort and excluded cohort).
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gurgitation was more prevalent as the LV volume increased
across each treatment group.Group 1 (Baseline LVESVI<60 mL/m2)
Of the 148 patients in group 1, 82 had undergone CABG
alone and 66 CABG plus SVR. Neither treatment arm in thisTABLE 2. Changes in LV volumes and systolic function relative to baselin
Variable
Group 1 (<60 mL/m2; n ¼ 148) Gr
CABG
(n ¼ 82)
CABGþSVR
(n ¼ 66) (n
Mean LVESVI
Preoperative 49 48
Postoperative 50 47
P value* .75 .46
No reduction in ESVI (%) 51 41
>30% Reduction in ESVI (%) 22 26
Mean LVESVI
Preoperative 78 76 1
Postoperative 79 77 1
P value .51 .96
Mean LVEF
Preoperative 0.37 0.36
Postoperative 0.39 0.40
P value .18 .008
CABG,Coronary artery bypass grafting; EDVI, end-diastolic volume index;ESVI, end-systo
left ventricular end-systolic volume index; SVR, surgical ventricular reconstruction. *Pair
The Journal of Thoracic and Carsubgroup had a significant decrease in LVESVI at 4 months
postoperatively (Table 2 and Figure E4, A). At 4 months, in
those who had undergone CABG plus SVR, the mean LVEF
increased from 0.36 at baseline to 0.40, 26% of patients had
a greater than 30% reduction in LVESVI from baseline, and
41% had no reduction or an increase in LVESVI. The
patients who had undergone CABG alone had a smaller
change in LVEF (from 0.37 to 0.39), 22% had a greater
than 30% reduction in LVESVI, and 51% had no change
or an increase in LVESVI.Group 2 (Baseline LVESVI, 60-90 mL/m2)
Of the 203 patients in group 2, 114 had undergone CABG
alone and 89CABGplus SVR.The patients receivingCABG
plus SVR had a significant decrease in LVESVI at 4 months
(mean 15 mL/m2; P< .0001), but those receiving CABG
alone did not (Table 2 andFigureE4,B). In patients receiving
CABG plus SVR, the LVEF increased from 0.30 at baseline
to 0.36 at 4 months, 36% of the patients had a greater than
30% reduction in LVESVI from baseline, and 12% had no
reduction or an increase in LVESVI. Patients with CABG
alone had a smaller increase in LVEF (from 0.29 to 0.33),
18% had a greater than 30% reduction in LVESVI, and
nearly one half had no change or an increase in LVESVI.Group 3 (Baseline LVESVI>90 mL/m2)
Of the 204 patients in group 3, 100 had undergone CABG
alone and 104 CABG plus SVR. The patients receiving
CABG plus SVR had a significant decrease in ESVI at
4 months (mean, 32 mL/m2; P < .0001). The patients
receiving CABG alone had a mean decrease in ESVI of
18 mL/m2 (P<.0001; Table 2 and Figure E4, C). In the pa-
tients receiving CABG plus SVR, the LVEF increased frome LV end-systolic volume
oup 2 (60-90 mL/m2; n ¼ 203) Group 3 (>90 mL/m2; n ¼ 204)
CABG
¼ 114)
CABGþSVR
(n ¼ 89)
CABG
(n ¼ 100)
CABGþSVR
(n ¼ 104)
74 74 117 120
72 59 99 88
.45 <.0001 <.0001 <.0001
47 12 27 17
18 36 26 45
04 106 151 153
05 91 131 121
.86 <.0001 <.0001 <.0001
0.29 0.30 0.23 0.22
0.33 0.36 0.27 0.28
.001 <.0001 .0002 <.0001
lic volume index; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESVI,
ed t test.
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a greater than 30% reduction in LVESVI from baseline,
and 17% had no reduction or an increase in LVESVI. Pa-
tients receiving CABG alone also had a significant increase
in LVEF (from 0.23 to 0.27; P¼ .0002), 26% had a greater
than 30% reduction in LVESVI, and 27% had no change or
an increase in ESVI.
The mean change in the end-diastolic volume index from
baseline to 4 months in the 555 patients segregated by treat-
ment received was similar to the mean change in LVESVI
(Table 2).
Survival According to Baseline LVESVI: Effect of
SVR
Stratification of the 555 patients according to the 3 base-
line LVESVI subgroups revealed no statistically significant
survival benefit from SVR but suggested that patients with
relatively smaller ventricles did better with SVR than those
with larger ventricles (Figure E5). When the 148 patients
in group 1 with relatively smaller ventricles at baseline
(LVESVI< 60 mL/m2) were excluded from the survival
analysis, the Kaplan-Meier cumulative risk of death esti-
mate for the remaining 407 patients with an LVESVI of
60 mL/m2 or more did not show a statistically significant
difference in mortality between the 2 treatment groups
(HR, 0.96; 95% CI, 0.63-1.44; log-rank P ¼ .8253).
Survival According to Postoperative LVESVI: Effect
of SVR
Kaplan-Meier mortality estimates of the 555 patients
with paired LVESVI measurements, classified according
to the 4-month postoperative LVESVI, are presented in
Figure 1. This analysis indicated enhanced survival with
CABG plus SVR compared with CABG alone for patients
who achieved a 4-month ESVI of 70 mL/m2 or less and
a worse outcome for patients with a greater 4-month
LVESVI. The 4-year Kaplan-Meier mortality estimates
suggested that the 4-month postoperative LVESVI had little
effect on survival in patients undergoing CABG alone. In
patients treated with CABG plus SVR, a statistically signif-
icant reduction in mortality was achieved in those patients
attaining an ESVI of less than 60 mL/m2 compared with
CABG plus SVR patients attaining an ESVI of 60 mL/m2
or more (HR, 0.33; 95% CI, 0.17-0.62; log-rank
P ¼ .0004; Figure 2). This relationship was not significant
in patients treated with CABG alone (HR, 0.68; 95% CI,
0.41-1.15; log-rank P ¼ .1519; Figure E6).
A similar trend was observed regarding the magnitude of
decrease in LVESVI after CABG plus SVR, using a thresh-
old of 30% or more reduction in LVESVI. No statistically
significant difference was seen in survival between patients
treated with CABG alone versus CABG plus SVR; how-
ever, attainment of this threshold reduction appeared to be
more important for survival in patients with CABG plus1142 The Journal of Thoracic and Cardiovascular SurSVR (P ¼ .09) than in patients with CABG alone
(Figure 3 and Figure E7). Of the 555 patients, 64 receiving
CABG alone and 96 receiving CABG plus SVR achieved
a 30% or more reduction in ESVI.
A total of 145 patients had a change from baseline in the
LVESVI of 25 mL/m2 or less and 410 patients had a change
from baseline in the LVESVI of more than 25 mL/m2. There
appeared to be little effect fromSVRforwhether the 4-month
LVESVI showed a ‘‘small’’ ( 25 mL/m2) or ‘‘large’’ (>25
mL/m2) reduction in LVESVI, regardless of the baseline
LVESVI (Figure E5).
DISCUSSION
The beneficial effects of reverse remodeling reported
with medical therapy in patients with ischemic LV dysfunc-
tion resulted in the evolution of a surgical procedure to
reduce the LV volume and wall tension, with the expecta-
tion of a similar benefit. The objective of SVR is to create
a smaller left ventricle with a more natural elliptical shape.
The CABG plus SVR operation has been shown to reduce
the LV volume, increase the LVEF, and improve clinical
symptoms.6,11-13 On the basis of registry data and a small,
nonrandomized, case-control study, it was proposed that
SVR performed with CABG would provide patient benefit
beyond that of CABG alone.13 However, CABG plus
SVR had not been compared with CABG alone in a random-
ized clinical trial until STICH. Because the beneficial treat-
ment effects on reverse remodeling are well known to be
time dependent in ischemic heart failure, a 4-month point
was selected for endpoint analysis in STICH.8
Significant limitations to these analyses were present.
First, only 924 of the 1000 STICH patients had ameasurable
baseline ESVI. Second, only 555 patients had paired pre-
and postoperative studies of fair to excellent quality using
the same imaging modality. Third, the present analysis eval-
uated a broad range of baseline LVESVIs (22-231 mL/m2).
Fourth, structural and hemodynamic variables related to LV
function, such as the sphericity index, conicity index, extent
and severity of anterior wall asynergy, diastolic parameters,
mitral regurgitation, and the presence of viable myocardium
were not evaluated. Finally, factors related to the conduct of
surgery such as mitral valve surgery and the use of a patch
for SVR were not analyzed.
Change in LVESVI With CABG Plus SVR and
CABG Alone
In STICH, the likelihood of achieving any reduction in
LVESVI or a major reduction ( 30%) from baseline was
related to the baseline ESVI for each treatment assignment;
patients with the largest ventricles (group 3) were the most
likely and those with smallest ventricles (group 1) the least
likely. The magnitude of LVESVI reduction was signifi-
cantly greater with SVR across the entire spectrum of base-
line LVESVI. In fact, 42% of all CABG alone patients hadgery c November 2013
FIGURE 1. Rolling 4-year Kaplan-Meier (KM) estimates by operation received and postoperative (post-op) left ventricular end-systolic volume index
(LVESVI) for 555 patients with paired LVESVI data. Total group size, 150; increment, 1. CABG, Coronary artery bypass grafting; SVR, surgical ventricular
reconstruction.
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a number of SVR patients also had no change or an increase
in LVESVI at 4 months. It is important to recognize that
with either CABG alone or CABG plus SVR, no reduction
or an increase in LVESVI at 4 months could be explained by
the continued LV remodeling that occurs after operation. It
is for this reason that the follow-up point of 4 months in
STICH is so critical to understanding the results of SVR.
Many published reports, including the nonrandomized, ret-
rospective Reconstructive Endoventricular Surgery Return-
ing Torsion Original Radius Elliptical (RESTORE) group
data, assessed patients early after surgery and before hospi-
tal discharge, often within 1 week of surgery. Not only is the
early postoperative period recognized as a time of ongoing
hemodynamic change for patients with heart failure, but
also, insufficient time would have elapsed to assess the
full effect of the SVR procedure, including additional LV
remodeling.FIGURE 2. Cumulative risk of death: coronary artery bypass grafting plus su
ventricular end-systolic volume index (LVESVI) less than or 60 mL/m2. HR,
The Journal of Thoracic and CarEffect of CABG Alone on LV Remodeling, Function,
and Survival: Influence of LVESVI
Increasing LVESVI has been associated with worse sur-
vival in almost all studies in which patients with LV systolic
dysfunction have been reported, particularly in patients af-
ter myocardial infarction. The STICH data suggest that the
beneficial effects of CABG on reverse LV remodeling in-
crease as the preoperative LVESVI increases. In STICH,
coronary revascularization alone in patients with the largest
ventricles (LVESVI> 90 mL/m2) resulted in the greatest
mean reduction in LVESVI (18 mL/m2) compared with
all patients who had undergone CABG alone. Although
these reductions were statistically significant compared
with baseline, the clinical relevance of these reductions de-
pends on the baseline LVESVI. The reduction of 18 mL/m2
in the group 3 CABG alone patients with a baseline mean
LVESVI of 117 mL/m2 would be unlikely to produce clin-
ical benefit.rgical ventricular reconstruction patients (n ¼ 259) and postoperative left
Hazard ratio; CI, confidence interval.
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FIGURE 3. Cumulative risk of death: coronary artery bypass grafting (CABG) plus surgical ventricular reconstruction (SVR) and reduction in postoperative
left ventricular end-systolic volume index (LVESVI) less than or 30% of baseline LVESVI. HR, Hazard ratio; CI, confidence interval.
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alone in the STICH patients with the largest baseline
LVESVI one might conclude that viable nonfunctioning
myocardium appears to be greater in patients with a larger
baseline LVESVI and that this muscle can be recruited, un-
dergo reverse remodeling, andbecome functional after revas-
cularization. It is not known whether the amount of viable
myocardium and the extent of asynergy varied among the 3
LVESVI groups, which could also explain the variability
among the 3 groups in the reduction of LVESVI with
CABG alone.
Effect of SVR on LV Remodeling, Function, and
Survival: Influence of LVESVI
Di Donato and colleagues5 reported that a preoperative
LVESVI greater than 94 mL/m2 was the maximum baseline
LVESVI that could result in a less than 60 mL/m2 LVESVI
after surgery. Those data suggest that there might be a point
of no return for ventricular remodeling beyond which SVR,
despite achieving a volume reduction, is unlikely to reduce
the LVESVI sufficiently to provide benefit. This observa-
tion is consistent with recent evidence from the cardiac re-
synchronization therapy data, in which Carluccio and
colleagues14 showed that extensive LV remodeling/dilata-
tion at baseline was associated with poor functional im-
provement and more frequent cardiac events at follow-up.
The results of STICH support a lack of benefit of SVR
compared with CABG alone when SVR was performed
in patients with the largest ventricles (baseline LVESVI
> 90 mL/m2), despite obtaining significant reductions in
LVESVI. Patients with the largest ventricles (group 3)
who underwent CABG plus SVR had an average baseline
LVESVI of 120 mL/m2, which decreased to an average1144 The Journal of Thoracic and Cardiovascular SurLVESVI of 88 mL/m2. This represents a large reduction
(27% reduction in the mean value) and a significantly
greater reduction than that achieved with CABG alone,
without a survival benefit. Despite a large percentage of
LVESVI reduction, it is unknown whether the absence
of a survival benefit is attributable to the absolute value
of the LVESVI reduction. Also, it is unknown whether in
patients with the largest ventricles, surgeons were less vig-
orous with volume reduction for reasons that included
a concern for diastolic performance.
Patients with a baseline LVESVI less than 60 mL/m2
have been thought to be suboptimal candidates for SVR ow-
ing to the more limited capacity to reduce LVESVI. An
LVESVI of 60 mL/m2 is not a small ventricle, because
the normal ESVI is approximately 25 mL/m2. STICH has
been criticized for having included such patients.2,4 SVR
had less effect on LVESVI in these patients, with LVESVI
decreasing 30% or more in 26% of patients after SVR
and 41% having no reduction or an increase in LVESVI.
Despite this relative lack of reduction in LVESVI there
was no signal of harm and, if anything, a trend toward
improved outcomes with SVR in these patients
(Figure E5).7 Moreover, excluding patients with a baseline
ESVI less than 60 mL/m2 from the survival analysis had no
effect on treatment outcome.
Di Donato and colleagues5,6 suggested that 1 of the goals
of SVR is reconstruction of the ventricle to an LVESVI less
than 60 mL/m2. The results of STICH support this
observation and suggest that the postoperative cutoff for
benefit could be greater and closer to 70 mL/m2
(Figure 1). The 4-year Kaplan-Meier mortality estimates
indicated enhanced survival with CABG plus SVR for pa-
tients who achieved an LVESVI of 70 mL/m2 or less andgery c November 2013
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LVESVI. The 4-month postoperative LVESVI had little ef-
fect on survival in patients with CABG alone.
Why the survival curves in Figure 1 cross at close to
70 mL/m2 is speculative, but it might be that in some pa-
tients, the left ventricle continues to enlarge between the
early postoperative period when the RESTORE group per-
formed their follow-up echocardiograms and the 4-month
period when postoperative imaging was performed in
STICH. It is uncertain why attaining a smaller postoperative
LVESVI would provide a survival advantage with SVR and
not with CABG. In contrast, patients with a larger postoper-
ative LVESVI after SVR did worse than patients with a sim-
ilar LVESVI after CABG alone (Figure 1).
No difference was seen in survival between CABG alone
and CABG plus SVR according towhether the LVESVI was
decreased by 25 mL/m2 or more. However, a 30% or more
reduction in LVESVImight have a more important effect on
survival in patients with CABG plus SVR than in patients
with CABG alone (Figure 3 and Figure E7). In patients
with a baseline LVESVI greater than 90 mL/m2, the per-
centage of reduction in the average LVESVI compared
with baseline with SVR was 27%. In addition, 45% of pa-
tients with a baseline LVESVI greater than 90 mL/m2
achieved a reduction of 30% or more. We do not know
whether the surgeons were reluctant to more aggressively
reduce the LVESVI in these group 3 patients, thereby leav-
ing the postoperative LVESVI at a level insufficient to
achieve a survival benefit. An alternative is that the sur-
geons were sufficiently aggressive and did achieve greater
early postoperative reductions only to have reverse remod-
eling undermine the greater reductions by the 4-month end-
point analysis. The STICH data cannot reveal whether
greater LVESVI reductions were achieved at 1 week after
surgery only to enlarge with reverse remodeling at the 4-
month observation point.
Several major observations are evident from the present
post hoc STICH subgroup analysis. First, a postoperative
LVESVI of 70mL/m2 or less after CABG plus SVR resulted
in improved survival compared with CABG alone, and the
contrary was true with a postoperative LVESVI of 70 mL/
m2 or more. Second, in patients treated with CABG plus
SVR, those who achieved a postoperative LVESVI less
than 60mL/m2manifested statistically significant improved
survival compared with those CABG plus SVR and a post-
operative LVESVI of 60 mL/m2 or more. This was not true
for those treated with CABG alone. Third, compared with
CABG alone, survival after SVR was not influenced byThe Journal of Thoracic and Carwhether SVR achieved a large or small volume reduction
(< 25 or  25 mL/m2). Finally, in the limited number of
patients achieving a postoperative LVESVI reduction of
30% or more compared with baseline, CABG plus SVR
did not provide a statistically significant survival benefit
compared with CABG alone.CONCLUSIONS
SVR continues to have a role in the treatment of patients
with ischemic cardiomyopathy. In patients for whom SVR
is planned, survival will be improved in those achieving
a postoperative LVESVI of 70 mL/m2 or less. The very
large, extensively remodeled, left ventricle at baseline
might limit the ability of SVR to achieve a sufficient reduc-
tion in LVESVI and, therefore, to derive a clinical benefit.
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FIGURE E1. Paired left ventricular studies before and after operation in 979 surgical ventricular reconstruction hypothesis patients. CMR, Cardiac
magnetic resonance; core lab, Core Laboratories; ECHO, echocardiography; ESVI, end-systolic volume index; post-op, postoperative; RN, radionuclide;
SPECT, single photon emission computed tomography.
FIGURE E2. All-cause mortality by treatment received in Surgical Treatment for Ischemic Heart Failure. CABG, Coronary artery bypass grafting; SVR,
surgical ventricular reconstruction.
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FIGUREE3. Cumulative risk of death: 555 as-treated patients with same (paired) baseline and 4-month imaging modality. CABG, Coronary artery bypass
grafting; CI, confidence interval; HR, hazard ratio; SVR, surgical vascular reconstruction.
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FIGUREE4. Preoperative to postoperative change in left ventricular end-systolic volume index (LVESVI) by operation received for (A) patients with base-
line LVESVI less than 60 mL/m2, (B) patients with baseline LVESVI 60–90 mL/m2, and (C) patients with baseline LVESVI greater than 90 mL/m2. CABG,
Coronary artery bypass grafting; SVR, surgical vascular reconstruction; SD, standard deviation.
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FIGURE E4. (Continued)
FIGURE E5. All-cause mortality by left ventricular end-systolic volume index (LVESVI) group and change from preoperative (Pre-Op) LVESVI. CABG,
Coronary artery bypass grafting; SVR, surgical vascular reconstruction.
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FIGURE E6. Cumulative risk of death for coronary artery bypass grafting (CABG) alone patients and postoperative (Post) left ventricular end-systolic
volume index (LVESVI) less than or 60 mL/m2 or more. CI, Confidence interval; HR, hazard ratio.
FIGURE E7. Cumulative risk of death for coronary artery bypass grafting (CABG) alone patients and reduction in postoperative (Post) left ventricular
end-systolic volume index (LVESVI) less than or 30% or more of baseline LVESVI. CI, Confidence interval; HR, hazard ratio.
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TABLE E1. Characteristics of patients with paired imaging studies by treatment assignment
Variable
CABG alone (n ¼ 296) CABGþSVR (n ¼ 259)
ESVI<60
mL/m2
ESVI 60-90
mL/m2
ESVI>90
mL/m2
ESVI<60
mL/m2
ESVI 60-90
mL/m2
ESVI>90
mL/m2
Patients (n) 82 114 100 66 89 104
Age (y) 63.1  10.5 61.8  8.8 60.0  9.2 61.9  9.9 62.0  10.6 59.8  8.8
Female gender (%) 26 8 10 14 13 12
Previous MI (%) 89 86 79 80 93 88
Hypertension (%) 52 58 47 64 61 44
Diabetes (%) 38 30 32 32 29 28
LVEF 0.37  0.08 0.29  0.07 0.23  0.07 0.36  0.09 0.30  0.06 0.22  0.06
Angina class III or IV (%) 52 50 43 56 43 50
NYHA functional class III
or IV (%)
61 63 66 53 64 74
Triple vessel disease (%) 73 68 63 73 57 58
Average no. of grafts 3.2 3.3 3.2 3.3 2.9 2.8
MR 3þor 4þ (%) 11 17 29 2 19 23
Data presented as mean  standard deviation, unless otherwise noted. CABG, Coronary artery bypass grafting; ESVI, end-systolic volume index; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; MR, mitral regurgitation; NYHA, New York Heart Association; SVR, surgical ventricular reconstruction.
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